top of page
Blog
Dec 26, 20204 min read
NDR White Paper Issue 8: ALS and epigenetics
Nothing illustrates that change is the essence of life quite like the butterfly. How does this cloudless sulphur caterpillar, eating the...
30
Nov 20, 20207 min read
NDR White Paper Issue 7: Models of ALS
Cathleen Lutz (Jackson Laboratory) described ALS as a “complex disease and consists of a group of conditions unified by a common theme,...
33
Nov 5, 20204 min read
NDR White Paper Issue 6: Energy Metabolism
NDR is approaching ALS from multiple directions- in 2021 we have 17 active projects! What is fascinating is the emerging overlap between...
22
Aug 27, 20203 min read
NDR White Paper Issue 5: Activity of Thymosan
Immunonormalizing molecules thymopoietin and levamisole HCl Inflammation and regulation of inflammatory responses are necessary for life....
52
Aug 3, 20204 min read
NDR White Paper Issue 4: C9orf72
RAN Proteins The discovery of a repeat expansion1 in the C9orf72 gene is important because it is a model to explain central...
15
May 6, 20204 min read
NDR White Paper Issue 2: Treatments Are Lacking
NDR’s goals are simple, bring promising therapies to ALS patients and know which treatment is appropriate for a patient by evaluating...
20
Apr 30, 20203 min read
NDR White Paper Issue 1: Thymopoietin
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease of animals and man with life-altering consequences. The defining pathology...
54
bottom of page